With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
As part of his mission to see more financial transparency in medicine, Sen Grassley has asked eight top US medical schools about their policies on ghostwriting.
A dose-finding study saw what were characterized as low bleeding rates associated with triple-drug antithrombotic therapy that included the oral anticoagulant dabigatran in patients with a recent ACS event and other cardiovascular risk factors.
Publicly released report cards based on hospital performance did not result in a measurably greater systemwide improvement in two composite AMI or CHF process-of-care indicators in a Canadian study. But they did appear to stimulate some important changes in delivery of care that could have led to some better outcomes.
The use of coronary CT angiography in the emergency room can successfully triage at-risk chest-pain patients and can do so faster and less expensively than standard diagnostic testing.
The latest evidence for the treatment of STEMI and PCI has been incorporated into a fast-track update of US guidelines. But questions remain about the quality of some of the evidence informing the guidelines and about the composition of the writing committees.
Discussion is abounding on why cangrelor did not show benefit over clopidogrel despite the fact that it did inhibit platelet activity more effectively.
Ticagrelor, an investigational antiplatelet agent, may become a new standard of care for the management of patients with STEMI heading for primary PCI, said the lead investigator of the STEMI subset of the PLATO trial. Reporting the new findings here today, he said they were consistent with the overall PLATO results.
None of the eight platelet assays studied were able to predict bleeding, but four of the eight, based on ADP-induced platelet aggregation, produced results that correlated with adverse CV outcomes. By contrast, four tests that use shear-stress-induced adhesion-based methods were not predictive.
Inflation of the paclitaxel-delivering balloon followed by a bare-metal stent failed a randomized noninferiority test against the Cypher sirolimus-eluting stent in previously untreated coronary lesions.
Although neither CHAMPION-PCI nor CHAMPION-PLATFORM showed significant reductions in the primary end point with this new IV antiplatelet agent, some positive effects were seen, suggesting that the drug may yet have a future.
Now that the US House of Representatives has passed a healthcare reform bill, organized medicine anticipates another votepossibly next weekon a second bill that would rewrite Medicare's controversial sustainable-growth-rate formula for physician reimbursement.
Anticipation is building for full trial results from ARBITER 6-HALTS, plus a better understanding of what went wrong with cangrelor in the CHAMPION trials. Also in the lineup are updates from PLATO, RE-LY, ALLHAT, BARI 2D, STICH, CASCADE, POPULAR, HEARTMATE II, and many more. Indeed, this year's "late-breaking" sessions include more than 30 trials over five days.
Fast walkers should find themselves less likely to succumb to cardiovascular death, according to a new French study in older adults. Measuring general fitness in this way could easily be incorporated into a general global assessment of cardiovascular risk, say the researchers.
A new meta-analysis has suggested that clopidogrel reduces cardiovascular events and increases bleeding in both men and women, without significant differences between the sexes.
The latest recommendations for the treatment of ST-elevation MI issued by American cardiology associations and the European Society of Cardiology are compared and contrasted in a new paper.
The imaging study was the first to show that stenting a non-flow-limiting stenosis of an SVG may help slow or halt the accelerated atherosclerosis that takes place in these vessels. An accompanying editorial cautions that the study does little more than "infer a trend toward anatomic benefit."
UPDATED // An 1126-patient trial shows that SPECT and CAC scoring imaging tests are independent and complementary predictors of short- and long-term cardiac risk, respectively.
A US update on the perioperative use of beta blockers for noncardiac surgery is, says the lead author, "similar" to recent European guidance on this issue.
Just weeks before ARBITER-HALTS 6 results come out at AHA 2009, an MRI study suggests that niacin is better than placebo in statin-treated patients with low HDL, at least for reducing carotid wall area. Experts say they'd also like to see insights into niacin effects on lipid-rich plaque volumesthe more commonly seen end point with MRI.
Inflammatory responses contribute to coronary plaque rupture, thrombosis, and vascular occlusion. Some viruses have proteins that interfere with these inflammatory responses. Researchers have identified a viral-derived protein that may eventually be an anti-inflammatory treatment for coronary syndromes.
Two well-known observational registries highlight such changes in women and men over a decade or more: Do women younger than 55 still have an advantage over men in the same age group?
After a median follow-up of 12 years, MI rates were essentially the same among those treated with surgery and those who received conventional care for weight loss.
Women and men have the same rates of chest pain and other classic symptoms during ACS, although women are more likely to experience some other symptoms such as jaw and neck pain.
PLATO, CURRENT-OASIS 7, and further analyses of PPIs and thienopyridines; read Dr Prasad's review of recent data presented at ESC; and watch presentations by Drs Mehran, O'Donoghue, Storey, and Wiviott.
PLATO, CURRENT-OASIS 7, COGENT, recent meetings have seen some blockbuster presentations in the area of antiplatelet/antithrombotic therapy. What is your response to these data? Answer our 4 short polling questions and learn your peers' responses.
Patients presenting with STEMI represent a high-risk population. Thrombotic and bleeding complications contribute to mortality in these patients. Join Drs. Steg, Hamm, Hill, and Mehran as they discuss best practices for the treatment of STEMI patients with a focus on preventing bleeding complications.
In the US, each year over 1.4 million people will be hospitalized for unstable angina (UA) and non-ST-segment-elevation myocardial infarction (NSTEMI). Multiple antiplatelet agents have been developed to interfere with or inhibit the specific pathways of platelet activation and aggregation that lead to the development of UA and NSTEMI. Join Drs Newby, Popma, and Wiviot as they discuss.
Join Drs. Cannon, Gupta, Schampaert, and Le May as they discuss how data stemming from recent clinical trials are adding up for ACS patients in Canada intended for PCI. They review how clinical decision-making based on efficacy, safety, and patient profile is changing in light of antiplatelet therapies that are currently available and those that may be available in the near future.